Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of omega-3 polyunsaturated fatty acids (commonly found in fish oil) and risperidone, an atypical antipsychotic. Omega-3 fatty acids are known for their antioxidant and anti-inflammatory properties and have been studied as adjunctive therapy in neuropsychiatric disorders. Risperidone acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing symptoms of schizophrenia and bipolar disorder. Preclinical studies suggest that the combination may reduce oxidative stress markers (such as MDA and TNF-alpha) more effectively than either agent alone in animal models of schizophrenia[2][3]. There is no evidence this specific combination is marketed under a unique brand name or approved formulation; it has been studied experimentally for potential synergistic effects on behavior and brain biochemistry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on omega-3 + risperidone.